Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 3150-3157

  Palayoor, Sanjeewani T ^a   Tofilon, Philip J ^a   Coleman, C Norman ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; I 1892; IBUPROFEN; KETOROLAC; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CELL HYPOXIA; DOWN REGULATION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANOXIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IBUPROFEN; ISOENZYMES; KETOROLAC; MALE; MEMBRANE PROTEINS; MONOSACCHARIDE TRANSPORT PROTEINS; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; SULFONAMIDES; TIME FACTORS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0041464531     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Furuta, Y., Hunter, N., Barkley, T., Hall, E., and Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res., 48: 3008-3013, 1988.
2. Teicher, B. A., Bump, E. A., Palayoor, S. T., Northey, D., and Coleman, C. N. Signal transduction inhibitors as modifiers of radiation therapy in prostate carcinoma xenografts. Radiat. Oncol. Investig., 4: 221-230, 1996.
3. Palayoor, S. T., Bump, E. A., Calderwood, S. K., Bartol, S., and Coleman, C. N. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin. Cancer Res., 4: 763-771, 1998.
4. Milas, L., Kishi, K., Hunter, N., Mason, K., Masferrer, J. L., and Tofilon, P. J. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. (Bethesda), 91: 1501-1504, 1999.
5. Kishi, K., Petersen, S., Petersen, C., Hunter, N., Mason, K., Masferrer, J. L., and Tofilon, P. J. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res., 60: 1326-1331, 2000.
6. Petersen, C., Petersen, S., Milas, L., Lang, F. F., and Tofilon, P. J. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res., 6: 2513-2520, 2000.
7. Milas, L., Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin. Radiat. Oncol., 11: 290-299, 2001.
8. Thun, M. J., Henley, S. J., and Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. J. Natl. Cancer Inst. (Bethesda), 94: 252-266, 2002.
9. Lu, X., Xie, W., Reed, D., Bradshaw, W. S., and Simmons, D. L. Nonsteroidal anti-inflammatory agents drugs cause apoptosis and induce cyclooxygenases in chick embryo fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 7961-7965, 1995.
10. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Toumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res., 57: 2452-2459, 1997.
11. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., and Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60: 1306-1311, 2000.
12. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
13. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., and Tarnawski A. S., Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med., 5: 1418-1423, 1999.
14. Liu, X. H., Kirschenbaum, A., Yao, S., Lee, R., Holland, J. F., and Levine, A. C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol., 164: 820-825, 2000.
15. Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., and DuBois, R. N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Investig., 105: 1589-1594, 2000.
16. Leahy, K. M., Ornberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer, J. L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res., 62: 625-631, 2002.
17. Jones, M. K., Szabo, I. L., Kawanaka, H., Husain, S. S., and Tarnawski, A. S. von Hippel Landau tumor suppressor and HIF-1α: new targets of NSAIDs inhibition of hypoxia-inducid angiogenesis. FASEB J., 16: 264-266, 2002,
18. 2 tension. Proc. Natl. Acad. Sci. USA, 92: 5510-5514, 1995.
19. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., and Ratcliffe, P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and growth. Proc. Natl. Acad. Sci. USA, 94: 8104-8109, 1997.
20. 2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol., 15: 551-578, 1999.
21. Salceda, S., and Caro, J. Hypoxia-inducible factor-1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. J. Biol. Chem., 272: 22642-22647, 1997.
22. Huang, L. E., Gu, J., Schau, M., and Bunn, H. F. Regulation of hypoxia-inducible factor-1α is mediated by oxygen-dependent domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA, 95: 7987-7992, 1998.
23. Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., and Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitinin-proteasome pathway. J. Biol. Chem., 274: 6519-6525, 1999.
24. Maxwell, P. H., Wiesener, M. S., Chang, G., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond.), 399: 271-275, 1999.
25. 2 sensing. Science (Wash. DC), 292: 464-468, 2001.
26. 2-regulated prolyl hydroxylation. Science (Wash. DC), 292: 468-472, 2001.
27. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., and Whitelaw, M. L. Aspargine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science (Wash. DC), 295: 858-861, 2002.
28. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
29. Mazure, N. M., Chen, E. Y., Yeh, P., Laderoute, K. R., and Giaccia, A. J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res., 56: 3436-3440, 1996.
30. Jones, A., Fujiyama, C., Blanche, C., Vloore, J. W., Fuggle, S., Cranston, D., Bicknell, R., and Harris, A. L. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1α and hypoxia-inducible-factor-2α in human bladder tumors and cell lines. Clin. Cancer Res., 7: 1263-1272, 2001.
31. Harris, A. L. Hypoxia-a key regulatory factor in tumor growth. Nat. Rev., 2: 38-47, 2002.
32. Feldser, D., Agani, F., Iyer, N. V., Pak, B., Ferreira, G., and Semenza, G. L. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res., 59: 3915-3918, 1999.
33. Wiesener, M. S., Turley, H., Allen, W. E., William, C., Eckardt, K. U., Talks, K. L., Wood, S. M., Gatter, K. C., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., and Maxwell P. H., Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood, 92: 2260-2268, 1998.
34. Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K. C., and Harris, A. L. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer., 85: 881-890, 2001.
35. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliff, P. J., and Harris, A. L. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 157: 411-421, 2000.
36. Hockel, M., and Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic and molecular aspects. J. Natl. Cancer Inst. (Bethesda), 93: 266-276, 2001.
37. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastasis. Cancer Res., 59: 5830-5835, 1999.
38. Russo, A., Mitchell, J. B., Finkelstein, E., DeGraff, W. G., Spiro, I. J., and Gamson, J. The effects of cellular glutathione elevation on the oxygen enhancement ratio. Radiat. Res., 103: 232-239, 1985.
39. Meade, E. A., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem., 274: 8328-8334, 1999.
40. Wiesener, M. S., Munchehagen, P. M., Berger, I., Morgan, N. V., Roigas, J., Schwiertz, A., Jergensen, J. S., Gruber, G., Maxwell, P. H., Loning, S. A., Frei, U., Maher, E. R., Grone, H-J., and Eckardt, K-U. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor 1α in renal carcinomas. Cancer Res., 61: 5215-5222, 2001.
41. Fukumura, D., Xu, L., Chen, Y., Gohongi, T., Seed, B., and Jain, K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res., 61: 6020-6024, 2001.
42. Airley, R., Loncaster, J., Davidson, S., Bromley, M., Roberts, S., Patterson, A., Hunter, R., Stratford, I., and West., C. Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res., 7: 928-934, 2001.
43. Zhong, H., Agani, F., Baccala, A. A., Rioseco-Camacho, N., Isaacs, W. B., Simons, J. W., and Semenza G. L. Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Res., 58: 5280-5284, 1998.
44. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M., Simon, J. W., and Semenza, G. L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphotidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545, 2000.
45. Akakura, N., Kobayashi, M., Horiuchi, I., Suzuki, A., Wang, J., Chen, J., Niizeki, H., Kawamura, K., Hosokawa, M., and Asaka, M. Constitutive expression of hypoxia-inducible factor-1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res., 61: 6548-6554, 2001.
46. Zelzer, E., Levy, Y., Kahana, C., Shilo, B-Z., Rubinstein, M., and Cohen, B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1α/ARNT. EMBO J., 17: 5085-5094, 1998.
47. Richard, D. E., Berra, E., Gothie, E., Roux, D., and Pouyssegur, J. p42/44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem., 274: 32631-32637, 1999.
48. Jewell, U. R., Kvietikova, I., Scheid, A., Wenger, R. H., and Gassmann, M. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J., 15: 1312-1314, 2001.
49. Milas, L., Hunter, N., Furuta, Y., Nishiguchi, I., and Runkel, S. Antitumor effects of indomethacin alone and in combination with radiotherapy: role of inhibition of tumor angiogenesis. Int. J. Radiat. Biol., 60: 65-70, 1991.
50. Skopinska-Rozzewska, E., Piazza, G. A., Sommer, E., Pamukcu, R., Barcz, E., Filewska, M., Caban, R., Ruddzinski, P., Bogdan, J., Mlekodaj, S., and Sikorska, E. Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): a potential mechanism for their antineoplastic properties. Int. J. Tissue React., 20: 85-89, 1998.
51. Sawako, H., Tsujii, S., Tsujii, M., Gunawan, E. S., Sasaki, Y., Kawano, S., and Hori, M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Investig., 12: 1469-1477, 1999.
52. Gerber, H. P., Condorelli, F., Park, J., and Ferrara, N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem., 272: 23659-23667, 1997.
53. Pai, R., Szabo, I. L., Kawanaka, H., Soreghan, B. A., Jones, M. K., and Tarnawski, A. S. Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: a key to its antiangiogenic action? Mol. Cell. Biol. Res. Commun., 4: 111-116, 2000.
54. Chen, E. Y., Mazure, N. M., Cooper, J. A., and Giaccia, A. J. Hypoxia activates a platelet-derived growth factor receptor/phosphotidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res., 61: 2429-2433, 2001.
55. Ryan, H., Lo, J., and Johnson, R. S. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J., 17: 3005-3015, 1998.
56. Carmeliet, P., Dor, Y., Herbert, J., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., and Keshet, E. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature (Lond.), 394: 485-490, 1998.
57. Dong, Z., Venatachalam, M. A., Wang, J., Patel, Y., Saikumar, P., Semenza, G. L., Force, T., and Nishiyama, J. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. J. Biol. Chem., 276: 18702-18709, 2001.
58. Blagosklonny, M. V. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (Review). Int. J. Oncol., 19: 257-262, 2001.
59. Kung, A. L., Wang, S., Kilo, J. M., Kaelin, W. G., and Livingston, D. M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med., 6: 1335-1340, 2000.
60. Dachs, G. U., Coralli, C., Hart, S. L., and Tozer, G. M. Gene delivery to hypoxic cells in vitro. Br. J. Cancer, 83: 662-667, 2000.
61. Rapisarda, A., Uranchimeg, B., Scudiero, D. A., Selby, M., Sausville, E. A., Shoemaker, R. H., and Melillo, G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res., 62: 4316-4324, 2002.
62. Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simmons, J. W., and Zhong, H. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res., 62: 2478-2482, 2002.
63. Isaacs, J. S., Jung, Y., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem., 277: 29936-29944, 2002.